EZH2 and myocardial infarction: To gain further insight into the potential therapeutic clinical applications of EZH2 inhibition post-MI, we isolated circulating monocytes from patients divided into three groups corresponding to (1) patients without coronary disease; (2) patients diagnosed with stable coronary artery disease (CAD); and (3) patients admitted after acute MI (AMI).